Placebo News and Research

RSS

DBV Technologies total revenues increase to €2,776,588 for full year 2012

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today its full year 2012 results, approved by the Board of Directors on March 1st, 2013.

4 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

KYTHERA Biopharmaceuticals, Inc. today announced four abstracts will be presented at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla.

2 Mar 2013

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Amoxicillin is a broad spectrum penicillin, and in the UK is one of the most frequently used antibiotics. It is commonly used either on its own or, where there are particular concerns about resistance, in combination as Co-amoxiclav (as Amoxicillin-clavulanic acid) which extends its anti-bacterial spectrum.

1 Mar 2013

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).

1 Mar 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Long-term treatment with spironolactone improves left ventricular diastolic function in HF patients

Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life, according to a study appearing in the February 27 issue of JAMA.

28 Feb 2013

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.

27 Feb 2013

CellAegis Devices to use autoRIC Device for Chronic Remote Ischemic Conditioning

CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC Device for Chronic Remote Ischemic Conditioning (CRIC).

27 Feb 2013

Ampio Pharmaceuticals starts Optina clinical trial

Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.

27 Feb 2013

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.

27 Feb 2013

Omega-3 fish oils could help protect against skin cancer

Taking omega-3 fish oils could help to protect against skin cancer, according to researchers at The University of Manchester.

27 Feb 2013

Shionogi receives FDA approval for Osphena to treat women with severe dyspareunia

The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.

26 Feb 2013

DHA supplementation during pregnancy reduces very low birth weight and early preterm delivery

University of Kansas researchers have found that the infants of mothers who were given 600 milligrams of the omega-3 fatty acid DHA during pregnancy weighed more at birth and were less likely to be very low birth weight and born before 34 weeks gestation than infants of mothers who were given a placebo. This result greatly strengthens the case for using the dietary supplement during pregnancy.

26 Feb 2013

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

26 Feb 2013

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.

26 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

Placebo News and Research

DBV Technologies total revenues increase to €2,776,588 for full year 2012

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

EpiCept fourth quarter revenue decreases to $0.1 million

Long-term treatment with spironolactone improves left ventricular diastolic function in HF patients

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

CellAegis Devices to use autoRIC Device for Chronic Remote Ischemic Conditioning

Ampio Pharmaceuticals starts Optina clinical trial

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Omega-3 fish oils could help protect against skin cancer

Shionogi receives FDA approval for Osphena to treat women with severe dyspareunia

DHA supplementation during pregnancy reduces very low birth weight and early preterm delivery

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Circassia announces results from ToleroMune cat allergy phase II clinical study

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News